Relationship of Advanced Holding Education and ADherence on antithrombotic in younger NVAF patients (ReAHEAD)

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS36807
• Study ID:
  36808
• Official title and acronym:
  Relationship of Advanced Holding Education and ADherence on antithrombotic in younger NVAF patients (ReAHEAD)
• DARWIN EU® study:
  No
• Study countries:
  Taiwan
• Study description:
  The objective of ReAHEAD study is to explore whether advanced educational interventions would improve adherence to dabigatran, in 12 months follow up period for AFib patients under 75 years old. it is a single country, multi-center, educational intervention randomized study to evaluate the adherence to dabigatran, for up to 12 months. Newly diagnosed patients with atrial fibrillation within 1 month, under 75 years old and newly prescribed with dabigatran on physician’ s decision will be randomized to receive standard of care or standard of care with additional education (1:1). We will measure adherence to dabigatran by MMAS-8 score (Chinese version).
• Study status:
  Finalised

Research institutions and networks

Institutions

Boehringer Ingelheim

Study timelines

Date when funding contract was signed

Planned:17/04/2020

Actual:17/04/2020

Study start date

Planned:11/09/2020

Actual:27/08/2020

Date of final study report

Planned:30/06/2023

Actual:16/02/2024

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim Taiwan Ltd.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

1160-0304